A 2.4 cm Lung Nodule with a Suspicious Hilar Node and Borderline Pulmonary Reserve

The hilar node is the key staging uncertainty. PET avidity in a hilar node can be inflammatory, but it can also be N1 disease, which changes the extent of resection and prognosis. I would start with endobronchial ultrasound-guided transbronchial needle aspiration of the right hilar node (station 10R) and the mediastinal stations 4R and 7. EBUS is the best first test because it can sample the hilar node that mediastinoscopy cannot easily reach, and it avoids a general anesthetic. If EBUS shows N1 disease, I would proceed to lobectomy with systematic nodal dissection rather than a wedge. If EBUS is negative but the hilar node remains suspicious, cervical mediastinoscopy is reasonable to exclude N2 disease, but it samples 2R, 4R, and 7, not 10R. Physiologic assessment is already fairly complete: ppoFEV1 0.95 L (31%) is borderline, DLCO 38% is low, and peak VO2 11 mL/kg/min is just above the usual 10 mL/kg/min threshold but well below normal. I would use the ppoFEV1 and VO2 together rather than either alone, and I would treat his exertional oxygen use and exacerbation history as additional risk markers.

He is a borderline candidate for lobectomy, not an obvious one. A ppoFEV1 of 31% and DLCO of 38% put him near the lower limit of acceptable resection, and peak VO2 of 11 mL/kg/min is only just above the threshold associated with acceptable perioperative risk. If the hilar node is N1, lobectomy with nodal dissection is oncologically standard and I would favor it, because a 2.4 cm tumor with N1 disease is not well treated by a wedge. If staging is N0, anatomic segmentectomy with adequate margins and nodal sampling is a reasonable compromise in a patient with limited reserve, but he should be told that lobectomy remains the more oncologically complete operation for a 2.4 cm tumor. SBRT is the alternative if he is deemed high risk for any resection or if he declines surgery. A wedge alone is not appropriate for a 2.4 cm adenocarcinoma with a suspicious hilar node. The decision should be made by a multidisciplinary team after EBUS staging, with explicit discussion of the trade-off between oncologic completeness and pulmonary reserve.

Preoperative optimization should be aggressive and time-limited. He needs smoking cessation, inhaled bronchodilators and steroids if he has COPD, pulmonary rehabilitation, nutritional support, and vaccination. I would treat his exertional hypoxemia and review whether he has cor pulmonale or pulmonary hypertension. Intraoperatively, I would use lung-protective ventilation with low tidal volumes, avoid fluid overload, and use regional analgesia such as a thoracic epidural or paravertebral block to permit early extubation. I would plan a muscle-sparing thoracotomy or VATS depending on the surgeon's expertise, and I would avoid unnecessary lung manipulation. Postoperatively, early mobilization, incentive spirometry, and careful oxygen titration are essential. Because his reserve is marginal, I would have a low threshold for ICU admission and noninvasive ventilation if he develops hypercapnia or respiratory failure. I would also discuss advance care planning and the possibility of prolonged air leak or bronchopleural fistula, which would be poorly tolerated in a patient with this degree of emphysema.